2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P3082
    SKF 106760 126053-71-2 98%
    SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis.
    SKF 106760
  • HY-P3162
    (Ala13)-Apelin-13 568565-11-7 98%
    (Ala13)-Apelin-13 is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 inhibits gastric motility through vagal cholinergic pathway.
    (Ala13)-Apelin-13
  • HY-P3168
    Martentoxin 98%
    Martentoxin, a 4,046 Da polypeptide toxin, is a large-conductance Ca2+-activated K+ (BKCa) channel inhibitor. Martentoxin attenuates NO release, inhibits iNOS activation and upregulates eNOS mRNA expression in HUVECs induced by TNF-α. Martentoxin can be used for vascular diseases research.
    Martentoxin
  • HY-P3228
    JKC 302 153982-38-8 98%
    JKC 302 is an ET-A receptor antagonist. JKC 302 partly blocks ET-1-induced contraction in asthmatic rat trachea ring.
    JKC 302
  • HY-P3346
    NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) 2891469-80-8 98%
    NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) (compound 39) is a potent APJ agonist, with a Ki of 0.6 nM. NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) can activate Gαi1 (EC50=0.8 nM) and recruit β-arrestin2 (EC50=31 nM). NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) exhibits prolonged cardiac effects.
    NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal)
  • HY-P3347
    NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) 2891469-81-9 98%
    NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) (compound 40), a macrocyclic analogue of Ape13, is a potent APJ agonist (Ki=5.7 nM). NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) exhibits a favorable Gα12-biased signaling and an increased in vivo half-life.
    NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal)
  • HY-P3388
    Utreglutide 2460862-12-6 98.42%
    Utreglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist. Utreglutide can lower blood pressure, blood lipids and body weight, and improve cardiovascular metabolism. Utreglutide can be used for research on type 2 diabetes or non-type 2 diabetes obesity.
    Utreglutide
  • HY-P3424
    NH2-AKK-COOH 158837-92-4 98%
    NH2-AKK-COOH, a synthetic tripeptide, is an ACE inhibitor, with IC50s of 0.090 μM, 0.178 μM, and 420.89 μM when FAPGG, HHL, and angiotensin-I are used as substrate respectively.
    NH2-AKK-COOH
  • HY-P3429
    SAMβA 2429946-75-6 98%
    SAMβA is conjugated to the cell permeable peptide TAT47-57. SAMβA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats.
    SAMβA
  • HY-P3433
    Sarafotoxin S6b 120972-53-4 98%
    Sarafotoxin S6b is a vasoconstrictor peptide, and a non-selective endothelin receptor agonist. Sarafotoxin S6b can induce contraction in isolated human coronary arteries , the Ki values of Coronary artery, Saphenous vein and Coronary artery are 0.27, 0.55 and 19.5 nM, respectively.
    Sarafotoxin S6b
  • HY-P3483
    Maxadilan 135374-80-0 98%
    Maxadilan is a specific irreversible PAC1 receptor agonist and a potent vasodilator peptide present in the salivary glands of sand flies. Maxadilan exhibits anti-apoptotic activity in hADSCs. Maxadilan inhibits pro-inflammatory cytokines (TNF-α) and enhances anti-inflammatory mediators (IL-10). Maxadilan can activate leukocytes and inhibit vascular permeability through PAC1 receptors. Maxadilan promotes neural differentiation of human adipose-derived stem cells. Maxadilan can be used to study endotoxin shock, atherosclerosis, and neurodegenerative diseases[1][2][3][4][5].
    Maxadilan
  • HY-P3537
    AGDV 99896-90-9 98%
    AGDV is the γ chain of fibrinogen. AGDV is critical for platelet aggregation.
    AGDV
  • HY-P3545
    5-Valine-angiotensin I 484-43-5 98%
    5-Valine-angiotensin I is an Ang I peptide belonging to angiotensin I. 5-Valine-angiotensin I induces muscle contraction, can be used for renin-angiotensin system studies. Angiotensin I is a putative neurotransmitter, is the precursor of angiotensin II and of angiotensin fragment 1-7, which are involved in regulation of fluid volume and the release of aldosterone.
    5-Valine-angiotensin I
  • HY-P3563
    [Lys4] Sarafotoxin S6c 1219444-22-0 98%
    [Lys4] Sarafotoxin S6c, a sarafotoxin analogue, is a potent and partial agonist of endothelin receptor. [Lys4] Sarafotoxin S6c elicits contraction of pig coronary artery, with an EC50 of 1.5 nM.
    [Lys4] Sarafotoxin S6c
  • HY-P3565
    Sarafotoxin S6d 1446991-36-1 98%
    Sarafotoxin S6d (STX-b) is a polypeptide toxin isolated from the venom of the Israeli sand boa constrictor. Sarafotoxin S6d induces multiple electrocardiogram (ECG) changes including myocardial ischemia and hyperkalemia. Sarafotoxin S6d induces strong extracellular calcium-dependent vasoconstriction in rat aorta and exhibits positive inotropic effects in rat atria. Sarafotoxin S6d can be used in the study of cardiovascular diseases.
    Sarafotoxin S6d
  • HY-P3593
    LPLRF-NH2 88280-21-1 98%
    LPLRF-NH2 is a member of RFamide peptide with anorexigenic effect. LPLRF-NH2 increases arterial blood pressure and modulates the electrical activity of brainstem neurons.
    LPLRF-NH2
  • HY-P3615
    [Asn18] Endothelin-1, human 309245-97-4 98%
    [Asn18] Endothelin-1, human is a peptide. Endothelin-1 is a major isoform of Endothelin and plays an important role for regulation of vascular function.
    [Asn18] Endothelin-1, human
  • HY-P3649
    D-Val-Leu-Lys-chloromethylketone 75590-15-7 98%
    D-Val-Leu-Lys-chloromethylketone is a polypeptide containing three amino acids. D-Val-Leu-Lys-chloromethylketone can act as an anticoagulant.
    D-Val-Leu-Lys-chloromethylketone
  • HY-P3712
    Cardioexcitatory peptide 1 127122-98-9 98%
    Cardioexcitatory peptide 1 is a cardioexcitatory neuropeptide, can be isolated from Achatina atria. Cardioexcitatory peptide 1 has potent cardio-excitatory action on the hearts and also modifies the motility of muscular tissues and neural activities.
    Cardioexcitatory peptide 1
  • HY-P3733
    Big Endothelin-1 (22-38), human 124932-61-2 98%
    Big Endothelin-1 (22-38), human is derived from human, is the 22-38 fragment of Big Endothelin-1 (ET-1) (1-38). Big ET-1 (1-38) is a propeptide of ET-1, which has potent and long-lasting vasoconstrictor effects, equips a specific enzymatic cleavage of the 38 amino acid chain to form ET-1 (1-21) and the C-terminal fragment Big ET-1 (22-38).
    Big Endothelin-1 (22-38), human
Cat. No. Product Name / Synonyms Application Reactivity